Novadoz Pharmaceuticals LLC: FDA regulatory profile

Novadoz Pharmaceuticals LLC appears in 1 indexed U.S. FDA record: 1 drug-shortage entry (from 2 openFDA source rows), naming 1 distinct product. Latest dated event: a shortage record dated 2026-08-17. Observations run 2023-07-14 to 2026-08-17 — 1130 days, 2 dated records across 2 calendar years, busiest 2026 with 1. Shortages: 1 current, averaging 2 package lines each across 1 FDA therapeutic category, 2 strengths, 6 package NDCs and 1 brand name. 6 related firms and 4 adjacent shortage entries are linked below, each by a shared shortage entry, substance or therapeutic category. Every figure here is a count or a date computed from the indexed FDA datasets over a finite window: coverage-limited activity signals, never quality ratings or judgements about the firm. By year: 2026 (1), 2023 (1). Shortage entries include Lisdexamfetamine Dimesylate Tablet, Chewable (Current, since 2023-07-14, 2 lines). FDA therapeutic categories covered: Psychiatry. Strengths reported: 20 mg and 40 mg. Related firms include Alvogen, Elite Laboratories, Inc., Lannett Company Inc. and Mylan Pharmaceuticals Inc., A Viatris Company. This firm appears in 1 indexed record, which is below the threshold this site requires before treating a manufacturer page as a standalone regulatory profile (only 1 indexed record). The page is published so the record remains reachable and verifiable, and it links on to the underlying FDA records, but it is marked noindex and left out of the sitemap: a single appearance of a company name is not a regulatory history, and presenting it as one would overstate what the data supports. Should further records reference this firm in a later ingestion, the page becomes a full profile automatically.